Filing Details
- Accession Number:
- 0001209191-13-030969
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-06 15:25:51
- Reporting Period:
- 2013-06-05
- Filing Date:
- 2013-06-06
- Accepted Time:
- 2013-06-06 15:25:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
816284 | Celgene Corp /De/ | 86 Morris Avenue Summit NJ 07901 | No | No | Yes | No | |
1577650 | Celgene European Investment Co Llc | 86 Morris Avenue Summit NJ 07901 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-06-05 | 3,267,974 | $0.00 | 3,267,974 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2013-06-05 | 66,666 | $15.00 | 3,334,640 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series C Preferred Stock | Disposition | 2013-06-05 | 9,803,922 | $0.00 | 3,267,974 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct |
Footnotes
- Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into 1/3rd of a share of Common Stock without payment of further consideration. The shares had no expiration date.
- These shares are owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all shares. Celgene disclaims beneficial ownership of the securities except to the extent of its pencuniary interest therein.